Hostname: page-component-586b7cd67f-t7fkt Total loading time: 0 Render date: 2024-11-26T06:44:24.396Z Has data issue: false hasContentIssue false
  • English
  • Français

P02.317 Olanzapine versus risperidone: A prospective comparison of clinical and economic outcomes in schizophrenia

Published online by Cambridge University Press:  16 April 2020

E.T. Edgell ,
W.Scott Andersen ,
B.M. Johnstone ,
B. Dulisse ,
D. Revicki ,
A. Breier  and
S. Gavart
E.T. Edgell
Affiliation:
Eli Lilly and Company. Indianapolis;
W.Scott Andersen
Affiliation:
Eli Lilly and Company. Indianapolis;
B.M. Johnstone
Affiliation:
Eli Lilly and Company. Indianapolis;
B. Dulisse
Affiliation:
Eli Lilly and Company. Indianapolis;
D. Revicki
Affiliation:
Medlap International. Bethesda, USA
A. Breier
Affiliation:
Eli Lilly and Company. Indianapolis;
S. Gavart
Affiliation:
Eli Lilly and Company. Indianapolis;

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Symposia
Information
European Psychiatry , Volume 15 , Issue S2: Congress of the Association of European Psychiatrists , October 2000 , pp. 408s
Copyright
Copyright © European Psychiatric Association 2000
Submit a response

Comments

No Comments have been published for this article.